JCR Journal of Clinical Rheumatology

JCR Journal of Clinical Rheumatology is the clinical journal of the Pan American League of Associations for Rheumatology, published since 1995 and now issued in Philadelphia by Lippincott Williams & Wilkins, with a 2025 Journal Impact Factor of 1.9. Its opening letters abbreviate the journal's own name and have nothing to do with Journal Citation Reports, the Clarivate list in which its metrics appear.《临床风湿病学杂志》是泛美风湿病学会联盟的临床刊物，1995 年创刊，现由 Lippincott Williams & Wilkins 在费城出版，2025 年期刊影响因子为 1.9。刊名开头的三个字母是该刊自身名称的缩写，与科睿唯安发布期刊指标的《期刊引证报告》无关。

Scope

• The declared remit is clinical practice, meaning what a rheumatologist can act on in the consulting room, framed as practical reports rather than as laboratory studies with a clinical aside.刊物声明的范围落在临床实践，即风湿科医生在诊室里能直接采用的内容，形态为实用性报告，不取以临床为附注的实验室研究。

• Rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis form the backbone, with treat-to-target schedules, remission definitions and the everyday business of switching agents.类风湿关节炎、银屑病关节炎与中轴型脊柱关节炎构成主干，涉及达标治疗日程、缓解定义以及换药的日常操作。

• Systemic lupus erythematosus, Sjögren syndrome, systemic sclerosis and the inflammatory myopathies are covered through diagnosis, organ monitoring and the handling of flares across years of follow-up.系统性红斑狼疮、干燥综合征、系统性硬化症与炎性肌病经诊断、器官监测和长年随访中的复发处理进入版面。

• Vasculitis and the polymyalgia rheumatica spectrum, giant cell arteritis included, are treated as diagnostic problems first, since the choice of imaging or biopsy fixes the label before any drug is chosen.血管炎与风湿性多肌痛谱系（含巨细胞动脉炎）先作诊断问题处理，影像或活检的选择在用药之前就定了病名。

• Gout and calcium pyrophosphate deposition receive steady coverage, from urate targets and flare prophylaxis to the patient who cannot take febuxostat and the tophus that will not shrink.痛风与焦磷酸钙沉积病获得持续关注，从尿酸目标值与发作预防，到不能服用非布司他的患者和久不消退的痛风石。

• Osteoarthritis, regional pain syndromes and soft-tissue rheumatism appear in their practical dress, which means injection technique, orthoses, exercise prescription and the limits of each.骨关节炎、区域疼痛综合征与软组织风湿病以实用面貌出现，包括注射技术、支具、运动处方以及各自的适用边界。

• Osteoporosis sits inside the remit, particularly glucocorticoid-induced bone loss, fracture risk assessment and the sequencing questions that follow a course of bisphosphonate or denosumab.骨质疏松属于收录范围，尤其是糖皮质激素引起的骨量丢失、骨折风险评估，以及双膦酸盐或地舒单抗疗程之后的选择次序。

• Paediatric rheumatology and the transfer of adolescent patients into adult clinics are handled as clinical problems, with growth, schooling and adherence treated as part of the disease.儿童风湿病以及青少年患者向成人门诊的转接按临床问题处理，生长、学业与依从性都被算作疾病的一部分。

• Musculoskeletal ultrasound and magnetic resonance imaging are read for their effect on management, so a paper on synovial thickening has to say what changed at the next clinic visit.肌肉骨骼超声与磁共振影像按其改变处理方案的作用来取舍，滑膜增厚的论文须说明下次门诊因此做了什么调整。

• Biologic agents, Janus kinase inhibitors and biosimilars are followed through efficacy, infection risk, tapering and the practical question of what to do when a patient loses response.生物制剂、Janus 激酶抑制剂与生物类似药按疗效、感染风险、减量以及失效之后的处置来讨论。

• Case reports and brief reports carry unusual weight here, because one instructive patient may teach more about a rare overlap syndrome than a pooled analysis of forty of them.病例报告与简报在此分量不小，一位有教学价值的患者对罕见重叠综合征的说明力，常常胜过四十例的汇总分析。

• Access to rheumatology care across the Americas, teleconsultation and the shortage of specialists in smaller health systems are within scope, a line that follows from the league affiliation.美洲各地获取风湿病诊疗的机会、远程会诊以及小型卫生体系中专科医生的短缺都在范围之内，这条线索来自联盟背景。

• Education, patient-reported outcomes and the technology that reaches the clinic bench, from electronic records to infusion pumps, are admitted when they change what a physician does.教育、患者报告结局以及进入诊室的技术，从电子病历到输注泵，只要改变了医生的做法便可入选。

History

• Volume one, number one appeared in February 1995 from Williams & Wilkins in Baltimore, under the subtitle Practical Reports on Rheumatic & Musculoskeletal Diseases.首卷首期于 1995 年 2 月由巴尔的摩的 Williams & Wilkins 出版，副题定为《风湿病与肌肉骨骼疾病的实用报告》。

• The founding premise was carried by the subtitle itself, practical reports, which promised material a clinician could use rather than the laboratory work that filled the specialty's older journals.办刊前提写在副题里，所谓实用报告，承诺的是临床医生能直接采用的内容，而非填满本学科旧刊的实验室研究。

• It ran six times a year for its first fourteen volumes, and the National Library of Medicine still records the bimonthly schedule as the former frequency through 2008.最初十四个卷册每年出六期，美国国立医学图书馆至今把双月刊列为 2008 年以前的旧刊期。

• Williams & Wilkins was absorbed into Wolters Kluwer at the end of the 1990s, and the imprint became Lippincott Williams & Wilkins, working out of Philadelphia rather than Baltimore.Williams & Wilkins 在 1990 年代末并入 Wolters Kluwer，版头改为 Lippincott Williams & Wilkins，办公地点也从巴尔的摩转到费城。

• From the August 2002 issue the letters JCR were set at the head of the title, and abstracting services, citation styles and library catalogues have carried the abbreviation ever since.2002 年 8 月号起，JCR 三个字母被排进刊名之前，此后文摘服务、引文格式与图书馆目录都沿用了这个缩写。

• By the same period the journal had also become the official publication of the Pan American League against Rheumatism, the body now known as the Pan American League of Associations for Rheumatology.同一时期，刊物又成为泛美抗风湿联盟的正式出版物，该组织今称泛美风湿病学会联盟。

• That affiliation gave the title a hemispheric base, and its pages began to carry material from Latin America alongside the North American practice literature that had filled the early volumes.这一隶属关系为刊物铺开横跨美洲的基础，版面开始出现来自拉丁美洲的稿件，与填满早期卷册的北美临床文献并列。

• MEDLINE and PubMed took the journal from volume 11, number 1, in February 2005, more than a decade after the first issue had gone to press.MEDLINE 与 PubMed 从 2005 年 2 月的第 11 卷第 1 期开始收录，距首期付印已过十余年。

• In 2009 the print schedule moved to eight issues a year, which is why volume 15 runs to eight numbers while volume 14 stops at six.2009 年刊期改为每年八期，第 14 卷止于六期、第 15 卷增至八期，卷内编号由此不再对齐。

• Volume numbering has stayed continuous since 1995, so volume 30 belongs to 2024 and a citation can be dated from the volume alone.卷号自 1995 年起连续编排，第 30 卷对应 2024 年，只凭卷号就能推算出版年份。

• Supplements sit outside the eight regular numbers, and 2024 carried a ninth, labelled 7S, issued alongside the seventh.增刊不计入八期正刊，2024 年就多出一册编号 7S 的附刊，与第七期一同发行。

• Articles carry DOIs under the 10.1097 prefix with an RHU stem, so a paper from this title is easy to tell apart from the rest of the Lippincott medical list.论文的 DOI 使用 10.1097 前缀与 RHU 词干，因此本刊文章与 Lippincott 医学刊群中的其他论文容易区分。

• Two abbreviations circulate side by side, J Clin Rheumatol in the National Library of Medicine's index and JCR-J CLIN RHEUMATOL in the citation reports, so reference lists carry both.两个缩写并行使用，美国国立医学图书馆的索引写作 J Clin Rheumatol，引证报告写作 JCR-J CLIN RHEUMATOL，参考文献里两种都能见到。

• Open access arrived as an option taken at acceptance rather than as a conversion of the whole title, and about a tenth of recent articles carry a gold licence.开放获取以录用时的选项形式出现，整刊并未转换，近年约十分之一的论文带金色开放许可。

• The 2025 Journal Impact Factor is 1.9 against a five-year figure of 2.2, with a Journal Citation Indicator of 0.48 and a rank of 37 among 58 rheumatology titles.2025 年期刊影响因子为 1.9，五年影响因子 2.2，期刊引文指标 0.48，在 58 种风湿病学期刊中列第 37 位。

• The peak came in 2022 at 3.902, after 3.517 in 2021, and the two following years gave 2.4 and 1.8 before the present 1.9. About 74 articles a year now appear, drawing 2759 citations, and the cited half-life of 6.1 years marks a literature still consulted while current.峰值出现在 2022 年的 3.902，2021 年为 3.517，随后两年依次落到 2.4 与 1.8，本年度回到 1.9。每年约刊出 74 篇论文，最近一次统计的总被引为 2759 次，6.1 年的引用半衰期说明这批文献多在时效期内被查阅。

Editors

• Each issue opens with front matter that lists an editor-in-chief, a group of associate editors and an editorial board whose members hold posts in rheumatology divisions across the Americas.每期卷首列出主编、一组副编辑以及编委会名单，编委在美洲各地的风湿科任职。

• The league's name sits on the cover as sponsoring body, while the handling of a manuscript stays with the editorial office and the referees it selects.联盟名号作为主办方印在封面上，稿件的处理权留在编辑部与编辑部选定的审稿人手中。

• Manuscripts arrive through Editorial Manager, the platform used for this title, where authors register, upload a file and follow its progress without writing to the office.稿件经本刊使用的 Editorial Manager 系统提交，作者在系统内注册、上传并跟踪进度，无须与编辑部通信。

• The first filter is fit, and a paper that reports a mechanism with no consequence for management is likely to be returned before referees are approached.第一道筛选看选题是否合刊，只报告机制而无处理后果的论文，常在送审之前就被退回。

• Referees are often practising rheumatologists rather than laboratory scientists, so reports on a clinical paper tend to land on what the author would do differently in the next clinic.审稿人多为执业风湿科医生，实验室背景者次之，评审意见因此常落到作者下一次门诊的具体改法上。

• Reports reach the handling editor, who weighs them against the manuscript, and revision is the common outcome at first pass, with outright acceptance and rejection both rare.意见回到处理编辑手中，由其与稿件对照权衡，初次裁定以修改居多，直接录用或退稿都较少。

• Authors answer each point in a response letter, and a manuscript that has changed substantially goes back to the referees who raised the objections.作者以答复信逐条回应，改动较大的稿件会回到提出异议的审稿人手中。

• A rejected author may appeal in writing, and the editor-in-chief either reopens the file or confirms the decision after reading the reports again.被拒作者可以书面申诉，主编或重新开启审稿，或在重读意见之后维持原裁定。

• The article mix follows the title's clinical purpose, with original articles, reviews, brief reports, case reports, expert commentary and letters, plus short illustrated pieces used for teaching.栏目组合依循刊物的临床定位，包括论著、综述、简报、病例报告、专家述评与读者来信，另有短篇图文用于教学。

• Case reports survive here while other rheumatology journals have pushed them out, on the condition that the case carries a lesson and that any image comes with the patient's permission.在其他风湿病学期刊削减病例报告的时候，本刊仍保留这一体裁，前提是病例带有教学点，图片须经患者同意。

• Supplements are assembled by guest editors, usually around a meeting or a body of consensus work, and their papers pass the same review as the regular numbers.增刊由客座编辑组织，多围绕一次会议或一组共识文件，其中的论文与正刊走同样的评审。